Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by first author.
Page 7: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
1801 | 4 | 42 | 785 1999 BRITISH JOURNAL OF CANCER 79(1):114-118 Verheul HMW; Panigrahy D; Yuan J; D'Amato RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits | 17 | 33 |
1802 | 0 | 0 | 924 2000 BLOOD 96(11):296B-296B Vescio RA; Berenson JR Thalidomide is an effective agent for patients with primary amyloidosis. | 0 | 1 |
1803 | 0 | 0 | 974 2000 EUROPEAN HEART JOURNAL 21:367-367 Vescovo G; Ceconi C; Ferrari R; Ambrosio GB; Ravara B; Angelini A; Corti A; Rossini K; Sandri M; Leprotti C; Dalla Libera L Does thalidomide block apoptosis and prevent from the development of skeletal muscle myopathy in chronic heart failure? | 0 | 0 |
1804 | 5 | 25 | 1444 2002 EUROPEAN JOURNAL OF HEART FAILURE 4(4):455-460 Vescovo G; Ravara B; Angelini A; Sandri M; Carraro U; Ceconi C; Libera LD Effect of thalidomide on the skeletal muscle in experimental heart failure | 1 | 2 |
1805 | 1 | 6 | 1718 2003 EUROPEAN JOURNAL OF HAEMATOLOGY 70(3):198-199 Vicari P; Ribas C; Sampaio M; Arantes AM; Yamamoto M; Reis JB; Segreto RA; Bordin JO; Colleoni GWB Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? | 0 | 0 |
1806 | 7 | 10 | 350 1993 ARCHIVES OF INTERNAL MEDICINE 153(4):534-534 VICENTE T; ORTEGA A; MUNOZ P; DIAZ MD; BOUZA E INVITRO ACTIVITY OF THALIDOMIDE AGAINST MYCOBACTERIUM-AVIUM COMPLEX | 5 | 6 |
1807 | 0 | 0 | 105 1984 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 111(3):289-290 VIGNOLLY B; GENIAUX M; ROMMEL A; TEXIER L BEHCET DISEASE, NODOUS ERYTHEMA AND THALIDOMIDE | 0 | 0 |
1808 | 8 | 26 | 427 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):543-548 VILANOVA M; RIBEIRO A; CARNEIRO J; ARALACHAVES M THE EFFECTS OF THALIDOMIDE TREATMENT ON AUTOIMMUNE-PRONE NZB AND MRL MICE ARE CONSISTENT WITH STIMULATION OF THE CENTRAL IMMUNE-SYSTEM .2. | 4 | 5 |
1809 | 0 | 0 | 1441 2002 EUROPEAN JOURNAL OF CANCER 38:S53-S53 Villalona-Calero M; Duan W; Otterson G; Kleiber B; Hindman K; Shah M; Young D; Wu W; Kuhn J Thalidomide modulation of Irinotecan; an NF-kB dependent effect? | 0 | 0 |
1810 | 2 | 5 | 231 1988 DERMATOLOGICA 176(2):107-107 VIRABEN R; DUPRE A ERYTHEMA-NODOSUM FOLLOWING THALIDOMIDE THERAPY FOR BEHCET DISEASE | 1 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1811 | 5 | 8 | 1782 2003 LEUKEMIA 17(8):1669-1670 Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents | 1 | 1 |
1812 | 0 | 0 | 149 1985 FEDERATION PROCEEDINGS 44(6):1881-1881 VOGELSANG G; GORDON G; HORWITZ L; SANTOS G; HESS A IMMUNOSUPPRESSIVE ACTIVITY OF THALIDOMIDE | 0 | 2 |
1813 | 1 | 2 | 336 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(10):735-735 VOGELSANG GB THALIDOMIDE NEUROPATHY - REPLY | 2 | 2 |
1814 | 0 | 0 | 307 1991 EXPERIMENTAL HEMATOLOGY 19(6):553-553 VOGELSANG GB; BUJNOVSZKY C; BOUCHER C; LEONG K; JALALIAN M; HESS A; SANTOS GW INVITRO IMMUNOLOGICAL EFFECTS OF THALIDOMIDE | 0 | 0 |
1815 | 0 | 0 | 352 1993 BLOOD 82(10):A421-A421 VOGELSANG GB; COLVIN OM; ALTOMONTE V; PIANTADOSI S; HESS AD; SANTOS GW EFFECT OF THALIDOMIDE DOSE AND PLASMA-LEVEL ON PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
1816 | 8 | 21 | 334 1992 NEW ENGLAND JOURNAL OF MEDICINE 326(16):1055-1058 VOGELSANG GB; FARMER ER; HESS AD; ALTAMONTE V; BESCHORNER WE; JABS DA; CORIO RL; LEVIN LS; COLVIN OM; WINGARD JR; SANTOS GW THALIDOMIDE FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE | 166 | 253 |
1817 | 2 | 6 | 217 1987 TRANSPLANTATION PROCEEDINGS 19(1):2658-2661 VOGELSANG GB; HESS AD; GORDON G; BRUNDRETTE R; SANTOS GW THALIDOMIDE INDUCTION OF BONE-MARROW TRANSPLANTATION TOLERANCE | 24 | 32 |
1818 | 1 | 20 | 199 1986 TRANSPLANTATION 41(5):644-647 VOGELSANG GB; HESS AD; GORDON G; SANTOS GW TREATMENT AND PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH THALIDOMIDE IN A RAT MODEL | 47 | 71 |
1819 | 5 | 19 | 227 1988 BONE MARROW TRANSPLANTATION 3(5):393-398 VOGELSANG GB; HESS AD; SANTOS GW THALIDOMIDE FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 31 | 38 |
1820 | 2 | 6 | 236 1988 LANCET 1(8589):827-827 VOGELSANG GB; SANTOS GW; COLVIN OM; CHEN TL THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 12 | 25 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1821 | 1 | 7 | 200 1986 TRANSPLANTATION PROCEEDINGS 18(4):904-906 VOGELSANG GB; TAYLOR S; GORDON G; HESS AD THALIDOMIDE, A POTENT AGENT FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 19 | 27 |
1822 | 4 | 8 | 249 1988 TRANSPLANTATION PROCEEDINGS 20(2):226-228 VOGELSANG GB; WELLS MC; SANTOS GW; CHEN TL; HESS AD COMBINATION LOW-DOSE THALIDOMIDE AND CYCLOSPORINE PROPHYLAXIS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN A RAT MISMATCHED MODEL | 14 | 16 |
1823 | 9 | 24 | 1282 2002 AKTUELLE NEUROLOGIE 29(3):149-152 Vogt T; Nill M; Hundsberger T Thalidomide neuropathy | 0 | 0 |
1824 | 2 | 12 | 87 1983 HAUTARZT 34(4):175-178 VOLCPLATZER B; WOLFF K TREATMENT OF SUBACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 3 | 6 |
1825 | 69 | 104 | 1826 2003 SWISS MEDICAL WEEKLY 133(5-6):77-87 von Moos R; Stolz R; Cerny T; Gillessen S Thalidomide: from tragedy to promise | 1 | 1 |
1826 | 1 | 26 | 1248 2001 NEUROTOXICOLOGY AND TERATOLOGY 23(3):255-264 Vorhees CV; Weisenburger WP; Minck DR Neurobehavioral teratogenic effects of thalidomide in rats | 1 | 3 |
1827 | 0 | 0 | 420 1994 PANMINERVA MEDICA 36(1):1-4 VOSGERAU JCB AUTOIMMUNITY IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND THE USE OF THALIDOMIDE | 3 | 3 |
1828 | 0 | 0 | 421 1994 PANMINERVA MEDICA 36(1):44-47 VOSGERAU JCB ATYPICAL HERPES SIMPLE - A SIGN OF TOXOPLASMOSIS ACTIVITY IN AIDS PATIENTS AND THE USE OF THALIDOMIDE | 0 | 1 |
1829 | 0 | 10 | 625 1997 JOURNAL OF PARENTERAL AND ENTERAL NUTRITION 21(4):233-234 Vromen A; Spira RM; Bercovier H; Berry E; Freund HR Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat | 0 | 2 |
1830 | 11 | 15 | 1872 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(2):149-155 Waage A; Gimsing P; Juliusson G; Turesson I; Gulbrandsen N; Eriksson T; Hjorth M; Nielsen JL; Lenhoff S; Westin J; Wisloff F; Nordic Myeloma Study Grp Early response predicts thalidomide efficiency in patients with advanced multiple myeloma | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1831 | 0 | 0 | 1351 2002 BLOOD 100(11):380B-380B Waage A; Romstad L; Brenne AT; Gimsing P; Juliusson G; Turesson I; Borset M; Sundan A Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 0 | 1 |
1832 | 18 | 27 | 992 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(5):383-388 Walchner M; Meurer M; Plewig G; Messer G Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus | 16 | 27 |
1833 | 1 | 2 | 73 1983 BRITISH MEDICAL JOURNAL 287(6400):1225-1225 WALKER W; LEWIS HBM; ALBERTRECHT F EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 0 | 0 |
1834 | 0 | 17 | 245 1988 TERATOLOGY 38(3):217-219 WARKANY J WHY I DOUBTED THAT THALIDOMIDE WAS THE CAUSE OF THE EPIDEMIC OF LIMB DEFECTS OF 1959 TO 1961 | 2 | 3 |
1835 | 7 | 10 | 718 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(2):293-295 Warren KJ; Nopper AJ; Crosby DL Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus | 7 | 9 |
1836 | 3 | 10 | 303 1991 BRITISH MEDICAL JOURNAL 303(6800):470-470 WATERS MFR USE OF THALIDOMIDE IN LEPROSY | 5 | 5 |
1837 | 0 | 0 | 343 1992 TROPICAL DOCTOR 22(3):139-140 WATERS MFR THALIDOMIDE PERIPHERAL NEUROPATHY - REPLY | 2 | 4 |
1838 | 0 | 0 | 1384 2002 BLOOD 100(11):808A-809A Weber D; Albitar M; Delasalle K; Dey A; Rankin K; Gavino M; Walker P; Alexanian R Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM). | 0 | 1 |
1839 | 0 | 0 | 1336 2002 BLOOD 100(11):209A-209A Weber D; Ginsberg C; Walker P; Obolendt M; Rankin K; Gavino M; Delasalle K; Alexanian R Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD). | 0 | 3 |
1840 | 7 | 22 | 1740 2003 JOURNAL OF CLINICAL ONCOLOGY 21(1):16-19 Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | 32 | 59 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1841 | 0 | 0 | 782 1999 BLOOD 94(10):604A-604A Weber DM; Gavino M; Delasalle K; Rankin K; Giralt S; Alexanian R Thalidomide alone or with dexamethasone for multiple myeloma. | 0 | 27 |
1842 | 0 | 0 | 905 2000 BLOOD 96(11):168A-168A Weber DM; Rankin K; Gavino M; Delasalle K; Aguayo A; Albitar M; Alexanian R Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). | 0 | 10 |
1843 | 0 | 0 | 902 2000 BLOOD 96(11):167A-167A Weber DM; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide with dexamethasone for resistant multiple myeloma. | 0 | 26 |
1844 | 12 | 17 | 1791 2003 LEUKEMIA & LYMPHOMA 44(7):1147-1149 Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma | 1 | 1 |
1845 | 0 | 0 | 1102 2001 BLOOD 98(11):162A-162A Wechalekar AD; Sutton D; Voralia M; Stewart AK; Chen CI Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. | 0 | 5 |
1846 | 0 | 0 | 806 1999 GASTROENTEROLOGY 116(4):A843-A843 Wedel S; Bauditz J; Suk A; Lochs H Efficacy of thalidomide in Crohn's disease. | 2 | 3 |
1847 | 11 | 52 | 1765 2003 JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
1848 | 11 | 35 | 370 1993 MOLECULAR AND CELLULAR BIOCHEMISTRY 129(2):195-200 WEGLICKI WB; STAFFORD RE; DICKENS BF; MAK IT; CASSIDY MM; PHILLIPS TM INHIBITION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE IN MAGNESIUM-DEFICIENCY | 4 | 9 |
1849 | 19 | 32 | 1762 2003 JOURNAL OF RHEUMATOLOGY 30(12):2627-2631 Wei JCC; Chan TW; Lin HS; Huang F; Chou CT Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial | 0 | 1 |
1850 | 9 | 12 | 494 1996 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 53(4):368-& Weidle PJ Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus | 5 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1851 | 12 | 23 | 833 1999 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
1852 | 0 | 0 | 20 1981 JOURNAL OF POST KEYNESIAN ECONOMICS 3(3):459-462 WEINTRAUB S THE CARTER ECONOMIC COUNCILS THALIDOMIDE TIP | 0 | 0 |
1853 | 0 | 32 | 27 1981 REHABILITATION 20(3):128-132 WEINWURMKRAUSE EM PARTNERSHIP AND SEXUALITY OF THALIDOMIDE-AFFECTED YOUNG-PEOPLE | 0 | 0 |
1854 | 0 | 18 | 28 1981 REHABILITATION 20(4):159-164 WEINWURMKRAUSE EM THE SITUATION OF THALIDOMIDE-AFFECTED YOUNG-PEOPLE IN CHOOSING AN OCCUPATION | 0 | 2 |
1855 | 3 | 19 | 465 1995 JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 674(2):287-292 Weinz C; Blaschke G Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis | 11 | 24 |
1856 | 0 | 0 | 616 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):20-20 Welles L; Little R; Wyvill K; Pluda J; Figg W; Lietzau J; Merced T; Humphrey R; Yarchoan R Preliminary results of a phase II study of oral thalidomide in patients with HIV infection and Kaposi's sarcoma (KS) | 2 | 3 |
1857 | 17 | 19 | 998 2000 JOINT BONE SPINE 67(4):259-261 Wendling D; Toussirot E; Michel F Thalidomide: a comeback? | 1 | 4 |
1858 | 0 | 0 | 485 1995 SEARCH 26(10):290-290 WESTMORE A HEREDITY OF THALIDOMIDE DEFORMITY DISPUTED | 0 | 0 |
1859 | 2 | 5 | 631 1997 LANCET 350(9089):1445-1446 Wettstein AR; Meagher AP Thalidomide in Crohn's disease | 35 | 53 |
1860 | 0 | 0 | 628 1997 JOURNAL OF WOMENS HEALTH 6(6):614-615 White K Thalidomide may be approved after decades-long US ban | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1861 | 1 | 4 | 311 1991 LANCET 337(8738):436-437 WILLIAMS I; WELLER IVD; MALIN A; ANDERSON J; WATERS MFR THALIDOMIDE HYPERSENSITIVITY IN AIDS | 26 | 34 |
1862 | 8 | 12 | 1403 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(1):128-130 Wilson EA; Jobanputra S; Jackson R; Parker AN; McQuaker IG Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report | 1 | 3 |
1863 | 0 | 0 | 730 1998 MOLECULAR BIOLOGY OF THE CELL 9:200A-200A Wilson K; Lancaster T; Boyd M; Taylor LD Inhibition of cell-cell contacts in T lymphoblastic cells during exposure to thalidomide. | 0 | 0 |
1864 | 4 | 15 | 260 1989 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 488(2):417-425 WINCKLER K; KLINKMULLER KD; SCHMAHL HJ DETERMINATION OF THE THALIDOMIDE ANALOGS 2-(2,6-DIOXOPIPERIDINE-3-YL)PHTHALIMIDINE (EM 12), 2-(2,6-DIOXOPIPERIDINE-4-YL)PHTHALIMIDINE (EM 16) AND THEIR METABOLITES IN BIOLOGICAL SAMPLES | 7 | 7 |
1865 | 0 | 13 | 103 1984 ACTA DERMATO-VENEREOLOGICA 64(5):412-417 WINKELMANN RK; CONNOLLY SM; DOYLE JA; PADILHAGONCALVES A THALIDOMIDE TREATMENT OF PRURIGO NODULARIS | 17 | 27 |
1866 | 1 | 5 | 328 1992 LANCET 339(8789):365-365 WINTER W; FRANKUS E THALIDOMIDE ENANTIOMERS | 12 | 18 |
1867 | 18 | 31 | 1838 2004 ANNALS OF HEMATOLOGY 83(7):467-470 Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide | 0 | 0 |
1868 | 13 | 22 | 517 1996 CHIRALITY 8(5):390-396 Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues | 28 | 34 |
1869 | 3 | 9 | 636 1997 NATURE 385(6614):303-304 Wnendt S; Zwingenberger K Thalidomide's chirality | 9 | 16 |
1870 | 13 | 15 | 1496 2002 JOURNAL OF INFECTIOUS DISEASES 185(9):1359-1363 Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H; Natl Inst Allergy Infect Dis AIDS Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267 | 5 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1871 | 0 | 0 | 711 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):516-516 Wolkenstein P; Latarget J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Milpied B; Bocquet H; Revuz J Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: Overmortality in treated group. | 0 | 0 |
1872 | 8 | 28 | 726 1998 LANCET 352(9140):1586-1589 Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis | 39 | 79 |
1873 | 0 | 0 | 1127 2001 BLOOD 98(11):313B-313B Womeldorph JL; Myhand RC; Monahan BP Reversible acute renal failure following initiation of thalidomide therapy in a patient with relapsed multiple myeloma. | 0 | 0 |
1874 | 0 | 0 | 624 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):797-797 Wong J; Brocato D; Kumar R The effect of thalidomide on murine hemangioendothelioma | 0 | 0 |
1875 | 11 | 38 | 287 1990 LEUKEMIA RESEARCH 14(5):395-399 WOOD PMD; PROCTOR SJ THE POTENTIAL USE OF THALIDOMIDE IN THE THERAPY OF GRAFT-VERSUS-HOST DISEASE - A REVIEW OF CLINICAL AND LABORATORY INFORMATION | 17 | 26 |
1876 | 4 | 9 | 1672 2003 BRITISH JOURNAL OF DERMATOLOGY 148(3):601-602 Worm M; Kolde G Schnitzler's syndrome: successful treatment of two patients using thalidomide | 0 | 0 |
1877 | 0 | 0 | 1936 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(3):P78-P78 Wu JJ; Pang KR; Hsu S; Tyring SK Thalidomide: A review of new indications | 0 | 0 |
1878 | 0 | 0 | 774 1999 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
1879 | 4 | 30 | 142 1985 BRITISH JOURNAL OF DERMATOLOGY 112(4):475-480 WULFF CH; HOYER H; ASBOEHANSEN G; BRODTHAGEN H DEVELOPMENT OF POLYNEUROPATHY DURING THALIDOMIDE THERAPY | 66 | 85 |
1880 | 0 | 37 | 93 1983 PERSPECTIVES IN BIOLOGY AND MEDICINE 27(1):93-106 WYATT HV DID THALIDOMIDE PROMOTE POLIOMYELITIS FOLLOWING ORAL POLIOVIRUS VACCINATION IN WEST-BERLIN IN 1960 | 0 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1881 | 10 | 21 | 1491 2002 JOURNAL OF COMBINATORIAL CHEMISTRY 4(2):149-153 Xiao ZL; Schaefer K; Firestine S; Li PK Solid-phase synthesis of thalidomide and its analogues | 0 | 4 |
1882 | 0 | 0 | 1063 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U659-U659 Xiao ZL; Schaefer K; Li PK Solid phase synthesis of thalidomide and its analogs. | 0 | 0 |
1883 | 0 | 0 | 777 1999 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
1884 | 24 | 39 | 1389 2002 BLOOD 100(12):4162-4168 Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J Antimyeloma efficacy of thalidomide in the SCID-hu model | 1 | 6 |
1885 | 0 | 0 | 899 2000 BLOOD 96(11):167A-167A Yakoub-Agha I; Attal M; Dumontet C; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux I; Bay JO; Monconduit M; Harousseau JL; Duguet C; Facon T Thalidomide in patients with advanced myeloma: Survival prognostic factors. | 0 | 11 |
1886 | 0 | 0 | 1859 2004 BONE MARROW TRANSPLANTATION 33:S156-S156 Yakoub-Agha I; Mohty M; Attal M; Marit G; Bulabois C; Sotto JJ; Gratecos N; Rio B; Vernant JP; Facon T; Jouet JP; Intergrp Francophne Myelome & SGFM Thalidomide as salvage therapy for relapsed multiple myeloma after allogeneic stem cell transplantation | 0 | 0 |
1887 | 0 | 0 | 1643 2003 BLOOD 102(11):456B-456B Yakoub-agha I; Mohty M; Attal M; Marit G; Bulabois CE; Sotto JJ; Gratecos N; Rio B; Vernant JP; Dib M; Garban F; Cahn JY; Jouet JP; Facon T Thalidomide (THAL) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT). | 0 | 0 |
1888 | 12 | 23 | 1829 2003 XENOTRANSPLANTATION 10(5):470-474 Yamamoto S; Cooper DKC An investigation of the effect of thalidomide on anti-gal antibody production in baboons | 0 | 0 |
1889 | 0 | 0 | 363 1993 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 34(4):1479-1479 YAN GC; PITTET N; HERBORT CP THE EFFECT OF THALIDOMIDE ON ENDOTOXIN-INDUCED UVEITIS IN RATS | 0 | 0 |
1890 | 0 | 0 | 1167 2001 CIRCULATION 104(17):123-123 Yang E; Matcuk G; Zhang Y; Talbi S; Chen M; Ho M; Liao C; Tsao PS; Quertermous T; Deng D; Sampas N; Ach R; Love W Anti-angiogenic effects of thalidomide characterized by transciptional profiling of endothelial cell-specific gene expression | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1891 | 0 | 0 | 493 1996 AMERICAN JOURNAL OF EPIDEMIOLOGY 143(11):6-6 Yang Q; Khoury MJ; James LM; Olney RS; Paulozzi LJ The return of thalidomide? Are birth defects surveillance systems ready? | 0 | 1 |
1892 | 3 | 44 | 573 1997 AMERICAN JOURNAL OF MEDICAL GENETICS 73(3):251-258 Yang QH; Khoury MJ; James LM; Olney RS; Paulozzi LJ; Erickson JD The return of thalidomide: Are birth defects surveillance systems ready? | 1 | 6 |
1893 | 0 | 0 | 1766 2003 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14:807A-807A Yaqub MS Acute renal failure in multiple myeloma patient receiving thalidomide and zoledronic acid infusion. | 0 | 0 |
1894 | 2 | 5 | 1758 2003 JOURNAL OF PEDIATRICS 143(5):692-694 Yasui K; Misawa Y; Shimizu T; Komiyama A; Kawakami T; Mizoguchi M Thalidomide therapy for juvenile-onset entero-Behcet disease | 0 | 1 |
1895 | 5 | 41 | 1734 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 22(1):165-173 Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells | 2 | 3 |
1896 | 0 | 0 | 929 2000 BLOOD 96(11):364A-364A Yata K; Otsuki T; Yamada O; Yawata Y Expression of angiogenic factors including VEGFs, effects of anti-VEGF-A MoAb, hypoxia, and thalidomide on myeloma cells. | 0 | 0 |
1897 | 0 | 42 | 147 1985 EUROPEAN JOURNAL OF PHARMACOLOGY 119(1-2):39-46 YOUDIM MBH; ASHKENAZI R SEROTONERGIC INVOLVEMENT IN PHARMACOLOGICAL ACTION OF THE ANXIOLYTIC-SEDATIVES THALIDOMIDE AND SUPIDIMIDE | 0 | 1 |
1898 | 3 | 5 | 256 1989 BRITISH MEDICAL JOURNAL 298(6671):432-432 YOULE M; CLARBOUR J; FARTHING C; CONNOLLY M; HAWKINS D; STAUGHTON R; GAZZARD B TREATMENT OF RESISTANT APHTHOUS ULCERATION WITH THALIDOMIDE IN PATIENTS POSITIVE FOR HIV ANTIBODY | 56 | 103 |
1899 | 1 | 4 | 286 1990 LANCET 335(8705):1591-1591 YOULE M; HAWKINS D; GAZZARD B THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 9 | 11 |
1900 | 0 | 0 | 1287 2002 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 59(18):1700-+ Young D Thalidomide prescribers cannot assign survey responsibility to pharmacists | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1901 | 1 | 1 | 1685 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):563-563 Younis T; Alam A; Paplham P; Spangenthal E; McCarthy P Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma (vol 121, pg 191, 2003) | 0 | 1 |
1902 | 3 | 5 | 1678 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):191-192 Younis TH Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma | 1 | 2 |
1903 | 0 | 0 | 1512 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:733A-734A Yudis M; Sirota RA; Stein HD; Snipes ER; Gronich JH; Ghantous VE; Collins DM Renal failure (RF) in multiple myeloma (MM) - Possible association with pamidronate and thalidomide. | 0 | 0 |
1904 | 3 | 6 | 1320 2002 BLOOD 99(11):4249-4249 Zangari M Thalidomide and thromboembolism - Response | 0 | 0 |
1905 | 3 | 5 | 1096 2001 BLOOD 98(5):1614-1615 Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy | 63 | 94 |
1906 | 0 | 0 | 923 2000 BLOOD 96(11):296B-296B Zangari M; Anaissie E; Desikan R; Badros A; Morris C; Munshi N; Gopal AV; Fink L; Spoon D; Tricot G; Barlogie B Thalidomide-induced hypercoagulability in multiple myeloma (MM). | 0 | 3 |
1907 | 3 | 16 | 1873 2004 BRITISH JOURNAL OF HAEMATOLOGY 126(5):715-721 Zangari M; Barlogie B; Anaissie E; Saghafifar F; Eddlemon P; Jacobson J; Lee CK; Thertulien R; Talamo G; Thomas T; Rhee FV; Fassas A; Fink L; Tricot G Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation | 0 | 0 |
1908 | 0 | 0 | 1371 2002 BLOOD 100(11):398A-398A Zangari M; Barlogie B; Anaissie FJ; Saghafifar F; Fassas A; Lee CK; Thertulien R; van Rhee F; Zeldis J; Fink L; Tricot G Abrogation of thrombogenic effect of the doxorubicin (DOX)- thalidomide (THAL) combination as part of total therapy II (TTII) for newley diagnosed multiple myeloma (MM) by effective anti-coagulation with low molecular weight heparin (LMWH). | 0 | 2 |
1909 | 0 | 0 | 1610 2003 BLOOD 102(11):236A-236A Zangari M; Barlogie B; Jacobson J; Rasmussen E; Burns M; Kordsmeier B; Shaughnessy JD; Anaissie EJ; Thertulien R; Fassas A; Lee CK; Schenkein D; Zeldis JB; Tricot G VTD regimen comprising velcade (V) plus thalidomide (T) and added DEX (D) for non-responders to V+T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. | 0 | 4 |
1910 | 0 | 0 | 1651 2003 BLOOD 102(11):687A-687A Zangari M; Barlogie B; Lee CK; Kang SH; Fassas A; Thertulien R; Van Rhee F; Talamo G; Burns M; Anaissie EJ; Tricot G; Jacobson J Increment in bone phophatase (ALP) in myeloma patients during treatment with velcade, thalidomide and dexamethasome (VTD) is a strong predictor for response. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1911 | 0 | 0 | 1331 2002 BLOOD 100(11):105A-105A Zangari M; Barlogie B; Prather J; Eddlemon P; Anaissie E; Lee CK; Tricot G; Thertulien R; van Rhee F Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. | 0 | 5 |
1912 | 4 | 20 | 1704 2003 CLINICAL LYMPHOMA 4(1):32-35 Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival | 3 | 6 |
1913 | 0 | 0 | 1099 2001 BLOOD 98(11):161A-162A Zangari M; Siegel E; Anaissie E; Saghafifar F; Morris C; Fink L; Barlogie B; Tricot G Risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (pts) treated with thalidomide (Thal): The Arkansas experience. | 0 | 4 |
1914 | 4 | 23 | 1322 2002 BLOOD 100(4):1168-1171 Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy | 19 | 33 |
1915 | 0 | 0 | 1203 2001 HAEMATOLOGICA 86(4):448-448 Zappasodi P; Lorenzi A; Corso A Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity | 1 | 1 |
1916 | 1 | 17 | 796 1999 CLINICAL THERAPEUTICS 21(2):319-330 Zeldis JB; Williams BA; Thomas SD; Elsayed ME STEPS (TM): A comprehensive program for controlling and monitoring access to thalidomide | 39 | 47 |
1917 | 11 | 28 | 1840 2004 ANNALS OF ONCOLOGY 15(1):134-138 Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou A; Mitsouli C; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A; Greek Myeloma Study Grp Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study | 1 | 1 |
1918 | 0 | 0 | 1637 2003 BLOOD 102(11):450A-450A Zervas K; Dimopoulos MA; Hatziharisi E; Anagnostopoulos A; Papaioannou M; Mitsouli C; Panagiotidis P; Korantzis L; Tzilianos M; Maniatis A Primary treatment of mutiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. | 0 | 0 |
1919 | 0 | 0 | 539 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):4015-4015 Zhang EP; Pleyer U; Hoffmann F; Hartmann C Effect of thalidomide on experimental keratoplasty | 0 | 0 |
1920 | 0 | 0 | 1451 2002 FERTILITY AND STERILITY 77(2):S28-S28 Zhong S; Shen K; Lang J The effects of thalidomide on interleukin-6 and vascular endothelial growth factor expression of endometrial stromal cell in vitro. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1921 | 7 | 37 | 1161 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(4):319-326 Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac | 2 | 10 |
1922 | 8 | 8 | 1700 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Zhou SF Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. | 0 | 0 |
1923 | 5 | 10 | 1714 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Zhou SF CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation | 0 | 0 |
1924 | 7 | 31 | 1162 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(6):541-544 Zhou SF; Kestell P; Tingle MD; Ching LM; Paxton JW A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide | 2 | 5 |
1925 | 102 | 164 | 1440 2002 DRUGS & AGING 19(2):85-100 Zhou SF; Kestell P; Tingle MD; Paxton JW Thalidomide in cancer treatment - A potential role in the elderly? | 4 | 5 |
1926 | 0 | 0 | 1438 2002 DRUG METABOLISM REVIEWS 34:148-148 Zhou SF; Li Y; Kestell P; Paxton JW Preliminary study of thalidomide transport by the human intestinal cell line Caco-2 | 0 | 0 |
1927 | 57 | 70 | 1739 2003 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
1928 | 19 | 42 | 593 1997 CLINICAL NEUROPHARMACOLOGY 20(2):152-164 Zhu J; Bai XF; Mix E; vanderMeide PH; Zwingenberger K; Link H Thalidomide suppresses T-and B-cell responses to myelin antigen in experimental allergic neuritis | 3 | 4 |
1929 | 15 | 33 | 741 1998 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 48(4):397-402 Zhu J; Deng GM; Diab A; Zwingenberger K; Bakhiet M; Link H Thalidomide prolongs experimental autoimmune neuritis in Lewis rats | 4 | 10 |
1930 | 15 | 45 | 1755 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(24):5222-5229 Zhu XX; Giordano T; Yu QS; Holloway HW; Perry TA; Lahiri DK; Brossi A; Greig NH Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1931 | 23 | 79 | 845 1999 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 425(1):153-167 Zhu XY; Zhang YP; Klopman G; Rosenkranz HS Thalidomide and metabolites: indications of the absence of 'genotoxic' carcinogenic potentials | 3 | 3 |
1932 | 2 | 6 | 943 2000 BONE MARROW TRANSPLANTATION 25(12):1319-1320 Zomas A; Anagnostopoulos N; Dimopoulos MA Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent | 18 | 32 |
1933 | 15 | 82 | 1309 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):20-30 Zorat F; Pozzato G Thalidomide in myelodysplastic syndromes | 3 | 3 |
1934 | 8 | 53 | 1158 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(4):881-894 Zorat F; Shetty V; Dutt D; Lisak L; Nascimben F; Allampallam K; Dar S; York A; Gezer S; Venugopal P; Raza A The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes | 14 | 23 |
1935 | 64 | 215 | 541 1996 JOURNAL OF INFLAMMATION 46(4):177-211 Zwingenberger K; Wnendt S Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations | 33 | 38 |
1936 | 1 | 1 | 22 1981 LANCET 2(8245):510-511 [Anon] THALIDOMIDE - 20 YEARS ON | 0 | 0 |
1937 | 0 | 5 | 122 1984 LANCET 2(8396):205-206 [Anon] DEBENDOX IS NOT THALIDOMIDE | 0 | 0 |
1938 | 5 | 15 | 163 1985 LANCET 2(8446):80-81 [Anon] THALIDOMIDE IN DERMATOLOGY AND LEPROSY | 7 | 0 |
1939 | 0 | 0 | 444 1995 CHEMISTRY IN BRITAIN 31(10):760-760 [Anon] THALIDOMIDE REVIVAL | 0 | 0 |
1940 | 0 | 0 | 453 1995 ENVIRONMENTAL HEALTH PERSPECTIVES 103(2):132-132 [Anon] RETHINKING THALIDOMIDE | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1941 | 0 | 0 | 454 1995 EUROPEAN CHEMICAL NEWS 63(1667):8-8 [Anon] GUINNESS TOPS UP THALIDOMIDE FUND | 0 | 0 |
1942 | 0 | 0 | 491 1996 AIDS PATIENT CARE AND STDS 10(1):51-51 [Anon] Thalidomide effective in treating AIDS-related mouth ulcers | 0 | 0 |
1943 | 0 | 0 | 492 1996 AIDS PATIENT CARE AND STDS 10(4):263-263 [Anon] Thalidomide trial for diarrhea | 0 | 0 |
1944 | 0 | 0 | 563 1997 AIDS PATIENT CARE AND STDS 11(4):292-292 [Anon] Limited course of thalidomide effective in treating AIDS-related mouth ulcers | 0 | 0 |
1945 | 0 | 0 | 564 1997 AIDS PATIENT CARE AND STDS 11(4):292-293 [Anon] Clinical sites initiated for thalidomide aphthous ulcer study | 0 | 0 |
1946 | 0 | 0 | 565 1997 AIDS PATIENT CARE AND STDS 11(4):296-296 [Anon] Positive results reported for thalidomide in AIDS wasting | 0 | 0 |
1947 | 0 | 1 | 571 1997 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 54(13):1485-1486 [Anon] Thalidomide heals HIV-related oral ulcers, but caution is required | 0 | 0 |
1948 | 0 | 0 | 585 1997 CHEMISTRY & INDUSTRY (18):714-714 [Anon] Thalidomide for US | 0 | 0 |
1949 | 0 | 0 | 598 1997 DRUG NEWS & PERSPECTIVES 10(8):506-506 [Anon] Celgene's thalidomide approvable for ENL | 0 | 0 |
1950 | 0 | 0 | 599 1997 EUROPEAN CHEMICAL NEWS 68(1780):51-51 [Anon] Celgene - FDA approves thalidomide's use against ENL | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1951 | 0 | 0 | 651 1997 SEARCH 28(8):239-239 [Anon] Inheriting thalidomide deformities | 0 | 0 |
1952 | 0 | 0 | 657 1998 AIDS PATIENT CARE AND STDS 12(3):231-231 [Anon] Thalidomide studied in asymptomatic patients | 0 | 0 |
1953 | 0 | 0 | 674 1998 BIOTECHNOLOGY LAW REPORT 17(3):361-362 [Anon] FDA grants orphan drug designation to thalidomide as treatment for primary brain cancers | 0 | 0 |
1954 | 0 | 0 | 675 1998 BIOTECHNOLOGY LAW REPORT 17(5):596-597 [Anon] Notorious teratogen wins FDA approval for leprosy - Thalidomide will be most tightly regulated drug ever | 0 | 0 |
1955 | 0 | 0 | 687 1998 CHEMISTRY & INDUSTRY (15):591-591 [Anon] Concern over US thalidomide approval | 1 | 0 |
1956 | 0 | 0 | 728 1998 MEDICAL LETTER ON DRUGS AND THERAPEUTICS 40(1038):103-104 [Anon] Thalidomide | 1 | 0 |
1957 | 0 | 0 | 732 1998 NATURE BIOTECHNOLOGY 16(8):695-695 [Anon] The problem with thalidomide's new incarnation | 0 | 0 |
1958 | 0 | 0 | 854 1999 ONCOLOGY-NEW YORK 13(5):744-744 [Anon] Thalidomide shows promising results in patients with multiple myeloma | 0 | 0 |
1959 | 0 | 0 | 951 2000 CA-A CANCER JOURNAL FOR CLINICIANS 50(1):3-3 [Anon] Once again, thalidomide in the news | 0 | 0 |
1960 | 0 | 0 | 955 2000 CHEMISTRY & INDUSTRY (16):522-522 [Anon] Health - Thalidomide patents granted in US | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1961 | 0 | 0 | 970 2000 DRUG NEWS & PERSPECTIVES 13(3):146-146 [Anon] Celgene's IMiDS and thalidomide show activity as COX-2 inhibitors | 1 | 0 |
1962 | 0 | 0 | 1034 2000 ONCOLOGY-NEW YORK 14(3):452-452 [Anon] Substantial activity of thalidomide in multiple myeloma, study shows | 0 | 0 |
1963 | 0 | 0 | 1035 2000 ONCOLOGY-NEW YORK 14(4):479-479 [Anon] Thalidomide active in advanced multiple myeloma | 0 | 0 |
1964 | 0 | 0 | 1036 2000 ONCOLOGY-NEW YORK 14(7):1081-1081 [Anon] Expanded data on thalidomide in advanced myeloma | 0 | 0 |
1965 | 0 | 0 | 1175 2001 CLINICAL LYMPHOMA 2(1):16-17 [Anon] Thalidomide shows promise in previously untreated and refractory multiple myeloma | 0 | 0 |
1966 | 16 | 47 | 1185 2001 DRUGS OF THE FUTURE 26(1):100-103 [Anon] Thalidomide - Synovir (R) - Thalomid (R) - Talizer (R) - Oncolytic treatment of IBD antiarthritic treatment of leprosy | 0 | 0 |
1967 | 1 | 1 | 1187 2001 EUROPEAN JOURNAL OF CANCER 37(16):1966-1966 [Anon] Thalidomide is back | 0 | 0 |
1968 | 0 | 2 | 1199 2001 HAEMATOLOGICA 86(4):348-348 [Anon] Thalidomide in the treatment of multiple myeloma | 0 | 0 |
1969 | 0 | 0 | 1252 2001 ONCOLOGY-NEW YORK 15(3):301-301 [Anon] Thalidomide analogs active against multiple myeloma | 0 | 0 |
1970 | 0 | 0 | 1253 2001 ONCOLOGY-NEW YORK 15(4):493-+ [Anon] Thalidomide studied in a variety of cancers and metabolic disorders | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1971 | 0 | 0 | 1418 2002 CHEMICAL & ENGINEERING NEWS 80(40):60-60 [Anon] Thalidomide and Frances Kelsey | 0 | 0 |
1972 | 14 | 22 | 1462 2002 HAEMATOLOGICA 87(4):345-346 [Anon] Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders | 0 | 0 |
1973 | 0 | 0 | 1601 2003 BIOTECHNOLOGY LAW REPORT 22(2):120-120 [Anon] Celgene, EntreMed agree to license for thalidomide analog - Companies will drop their infringement suits | 0 | 0 |
1974 | 0 | 0 | 1716 2003 EUROPEAN JOURNAL OF CANCER 39(7):854-854 [Anon] Thalidomide on trial | 0 | 0 |
1975 | 0 | 0 | 1767 2003 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |